Leqvio (Inclisiran) in ASCVD Guidelines: Evidence So Far
Inclisiran cuts LDL-C ~50%, but ORION-4 shows only modest event reduction versus PCSK9 antibodies. See dosing, mechanism, and guideline status.
Inclisiran: Off-Label Uses
3 source-based articles maintained by the HealthRX.com Editorial Team.
3articles
3topic areas covered
May 25, 2026latest review
Inclisiran: Off-Label Uses library
Showing 3 of 3 clinical reviews.
Leqvio for ASCVD Secondary Prevention: Off-Label Use, Evidence, and Dosing Protocol
A clinician-focused review of inclisiran (Leqvio) for ASCVD secondary prevention, covering off-label status, LDL-C efficacy data from ORION trials, dosing protocol, and guideline context.
Leqvio for FH: Who Guidelines Recommend It For
HeFH on max statins is FDA-approved for Leqvio (47.9% LDL-C drop, ORION-9); HoFH use is off-label, with ORION-5 showing about 19.8% reduction.